DEVON, Pa., March 09, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the acceptance and presentation details of three posters at the American Academy of Neurology (AAN) 2020 Annual Meeting. The meeting is being held in Toronto, Canada from April 25th through May 1, 2020.

“These new data at AAN provide additional information on the safety and observed experimental profile of activity of Zygel™ in the exploratory Phase 2 FAB-C trial in Fragile X syndrome and the Phase 2 BELIEVE 1 trial in developmental and epileptic encephalopathies, and the potential of Zygel to improve patient quality of life,” said Joseph Palumbo, MD, FAPA, MACPsych, Chief Medical Officer of Zynerba. “On behalf of the families and investigators participating in the Zygel clinical development program, we are excited to share these study findings and key learnings with the larger scientific community attending AAN this year.”

Wednesday, April 29 from 8:00 AM to 9:00 AM.

Poster Title: "Cannabidiol Transdermal Gel in Children and Adolescents with Developmental and Epileptic Encephalopathies: An Open-label Clinical Trial"
Abstract number: 1631
Poster session: P11
Poster grouping: Epilepsy/Clinical Neurophysiology (EEG): Antiepileptic Medications/Neurostimulation and Diet Therapies 1 (in Poster Neighborhood #4)
Presentation number: 007

Poster Title: "Quality of Life and Qualitative Caregiver Assessments in Children and Adolescents with Developmental and Epileptic Encephalopathies Treated with Cannabidiol Transdermal Gel: An Open-label Clinical Trial"
Abstract number: 1664
Poster session: P11
Poster grouping: Epilepsy/Clinical Neurophysiology (EEG): Antiepileptic Medications/Neurostimulation and Diet Therapies 1 (in Poster Neighborhood #4)
Presentation number: 006

Thursday, April 30 from 12:00 PM to 1:00 PM.

Poster Title: "Cannabidiol Transdermal Gel for the Treatment of Fragile X Syndrome: Post hoc Responder Analysis and Pattern of Efficacy on domains of the Aberrant Behavior Checklist-FXS (ABC-C_FXS)"
Abstract number: 4743
Poster session: P15
Poster grouping: Child Neurology and Developmental Neurology: Neurogenetics 3 (in Poster Neighborhood #11)
Presentation number: 002

About Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals is the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome, autism spectrum disorder, 22q11.2 deletion syndrome, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies. Learn more at www.zynerba.com and follow us on Twitter at @ZynerbaPharma.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company’s current expectations. These and other risks are described in the Company’s periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at www.sec.gov. Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Zynerba Contact
Will Roberts, VP Investor Relations and Corporate Communications
484.581.7489
robertsw@zynerba.com

Media contact
Molly Devlin
Evoke KYNE
215.928.2199
Molly.Devlin@evokegroup.com

Source: Zynerba Pharmaceuticals, Inc.